Omeros Corporation (NASDAQ:OMER) Q4 2025 Earnings Call Transcript April 1, 2026 Operator: Good afternoon, and welcome to today’s earnings call for Omeros Corporation. [Operator Instructions] Please be ...
Q4 2025 Earnings Call March 31, 2026 4:30 PM EDTCompany ParticipantsGregory Demopulos - Co-Founder, Chairman, CEO ...
8d
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the fourth quarter and year ...
Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the ...
Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026 ...
Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants ...
Photoreceptors are specialized neurons that convert light into electrical signals that are processed in the visual cortex to form images. The RPE is a cell layer that is adjacent to the photoreceptors ...
Advances To Final Cohort In Oncology Clinical Trial Following Positive DSMB Review. (Investorideas Newswire) a leading investment platform for retail investors reports breaking Medical Tech Stock news ...
Omeros, a biopharmaceutical company, marked a significant milestone in its fourth quarter of 2025 with two major successes ...
Novel immunotherapeutics have transformed oncology, moving away from broad, non-specific treatments toward highly ...
The oversubscribed round will support final assay development and manufacturing readiness for an early access program launch.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results